Palantir stock is once again a top performer across the S&P 500 and Nasdaq-100, but a sharp sell-off could be in store sooner than later.

(Reuters) -Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top ...

YieldMax's combination of high yield dividends and fast moving tech stock ETFs through synthetic derivative covered call ...

Elon Musk, Peter Thiel and David Sacks eagerly pursued political influence, and when President Donald Trump took power for ...

The Good Kind Of Job Destruction I’m honored to be friends with Joe Lonsdale, co-founder of Palantir and now a storied ...

The collaboration with OSL, a leading regulated platform in Asia, marks MoneyHero's strategic expansion into the digital asset landscape, empowering ...

A look at how the conservative billionaires have leveraged their wealth and connections to positions of power that aid their ...

Once seen as a global economic powerhouse, Britain’s status as a rich economy is now under serious question. This video ...

Palantir Technologies is currently worth $300 billion, but Shopify and Intuitive Surgical are growing quickly enough to top ...